Gameisover,

Unfortunately the Cardiogenics game is not over given the paucity of transparency and information provided in this 10K.

In addition to the points of interest you listed, the 10K also informed us that:

1. The MTA's for the beads are not close to commercialization (page 9); interesting that language was included indicating no significant revenue from beads anticipated until the POC and first cardiovascular test are commercialized (with which I agree and have posted on this board).
2. No information is provided on what entity or person purchased the 1,050,000 shares via the private placement (page 24)
3. A $300,000 line of credit has been established with JMJ Financial with very favorable terms for JMJ to convert to common stock (page 28)
4. Two officer/directors (Tabatenik and Reid?) advanced Cardiogenics under undisclosed terms $200,000 (page 28)

Hopefully we Shareholders will be informed by the end of Q1 2013 the following:

1. The closing of a PIPE that adequately funds the company thru development of the POC analyzer
2. Initiation of the head-to-head study of the POC analyzer

Ante